

Michael Friedlander

List of Publications by Citations

Source: <https://exaly.com/author-pdf/8660542/michael-friedlander-publications-by-citations.pdf>
Version: 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

188 papers	20,515 citations	56 h-index	142 g-index
202 ext. papers	24,703 ext. citations	6.7 avg, IF	6.27 L-index

#	Paper	IF	Citations
188	Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. <i>Lancet, The</i> , 2010 , 376, 235-44	40	1395
187	Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. <i>New England Journal of Medicine</i> , 2012 , 366, 1382-92	59.2	1265
186	Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. <i>Journal of Clinical Oncology</i> , 2015 , 33, 244-50	2.2	1171
185	Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. <i>Lancet, The</i> , 2010 , 376, 245-51	40	1089
184	Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. <i>New England Journal of Medicine</i> , 2018 , 379, 2495-2505	59.2	1061
183	Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. <i>Lancet Oncology, The</i> , 2014 , 15, 852-61	21.7	1007
182	Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. <i>Lancet Oncology, The</i> , 2017 , 18, 1274-1284	21.7	913
181	Rethinking ovarian cancer: recommendations for improving outcomes. <i>Nature Reviews Cancer</i> , 2011 , 11, 719-25	31.3	893
180	Whole-genome characterization of chemoresistant ovarian cancer. <i>Nature</i> , 2015 , 521, 489-94	50.4	890
179	Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet, The</i> , 2017 , 390, 1949-1961	40	815
178	BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group. <i>Journal of Clinical Oncology</i> , 2012 , 30, 2654-63	2.2	810
177	Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup. <i>Journal of Clinical Oncology</i> , 2009 , 27, 1419-25	2.2	547
176	Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial. <i>Lancet Oncology, The</i> , 2015 , 16, 87-97	21.7	405
175	Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIg). <i>International Journal of Gynecological Cancer</i> , 2011 , 21, 419-23	3.5	400
174	Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer. <i>Journal of Clinical Oncology</i> , 2012 , 30, 372-9	2.2	381
173	Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer. <i>New England Journal of Medicine</i> , 2019 , 381, 2403-2415	59.2	334
172	Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial. <i>Lancet Oncology, The</i> , 2016 , 17, 1579-1589	21.7	296

171	2010 Gynecologic Cancer InterGroup (GCIg) consensus statement on clinical trials in ovarian cancer: report from the Fourth Ovarian Cancer Consensus Conference. <i>International Journal of Gynecological Cancer</i> , 2011 , 21, 750-5	3.5	292
170	Incorporation of pazopanib in maintenance therapy of ovarian cancer. <i>Journal of Clinical Oncology</i> , 2014 , 32, 3374-82	2.2	245
169	Fertility- and menopause-related information needs of younger women with a diagnosis of early breast cancer. <i>Journal of Clinical Oncology</i> , 2005 , 23, 5155-65	2.2	213
168	Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk. <i>PLoS Genetics</i> , 2013 , 9, e1003212	6	209
167	A Phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer. <i>Gynecologic Oncology</i> , 2010 , 119, 32-7	4.9	199
166	"Platinum resistant" ovarian cancer: what is it, who to treat and how to measure benefit?. <i>Gynecologic Oncology</i> , 2014 , 133, 624-31	4.9	197
165	Secondary Somatic Mutations Restoring and Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma. <i>Cancer Discovery</i> , 2017 , 7, 984-998	24.4	193
164	Efficacy and safety of olaparib monotherapy in germline BRCA1/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy. <i>Gynecologic Oncology</i> , 2016 , 140, 199-203	4.9	188
163	IL6-STAT3-HIF signaling and therapeutic response to the angiogenesis inhibitor sunitinib in ovarian clear cell cancer. <i>Clinical Cancer Research</i> , 2011 , 17, 2538-48	12.9	182
162	Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial. <i>Lancet, The</i> , 2016 , 387, 1066-1074	4.0	170
161	Guidelines for the Treatment of Recurrent and Metastatic Cervical Cancer. <i>Oncologist</i> , 2002 , 7, 342-347	5.7	162
160	Clinical trials in recurrent ovarian cancer. <i>International Journal of Gynecological Cancer</i> , 2011 , 21, 771-5	3.5	147
159	It's now or never: fertility-related knowledge, decision-making preferences, and treatment intentions in young women with breast cancer--an Australian fertility decision aid collaborative group study. <i>Journal of Clinical Oncology</i> , 2011 , 29, 1670-7	2.2	141
158	The importance of patient-reported outcomes in clinical trials and strategies for future optimization. <i>Patient Related Outcome Measures</i> , 2018 , 9, 353-367	2.9	129
157	Biology of epithelial ovarian cancer: implications for screening women at high genetic risk. <i>Journal of Clinical Oncology</i> , 2004 , 22, 1315-27	2.2	128
156	Patient-reported outcome results from the open-label phase III AURELIA trial evaluating bevacizumab-containing therapy for platinum-resistant ovarian cancer. <i>Journal of Clinical Oncology</i> , 2014 , 32, 1309-16	2.2	127
155	The fertility- and menopause-related information needs of younger women with a diagnosis of breast cancer: a qualitative study. <i>Psycho-Oncology</i> , 2003 , 12, 500-11	3.9	120
154	Cancer of the ovary, fallopian tube, and peritoneum. <i>International Journal of Gynecology and Obstetrics</i> , 2018 , 143 Suppl 2, 59-78	4	116

153	Small cell of the ovary, hypercalcemic type -- analysis of combined experience and recommendation for management. A GCIIG study. <i>Gynecologic Oncology</i> , 2006 , 100, 233-8	4.9	108
152	Cancer-related fatigue in women with breast cancer: outcomes of a 5-year prospective cohort study. <i>Journal of Clinical Oncology</i> , 2012 , 30, 1805-12	2.2	99
151	Health-related quality of life and patient-centred outcomes with olaparib maintenance after chemotherapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT Ov-21): a placebo-controlled, phase 3 randomised trial. <i>Lancet Oncology, The</i> , 2018 , 19, 1126-1134	21.7	91
150	Cancer of the ovary, fallopian tube, and peritoneum. <i>International Journal of Gynecology and Obstetrics</i> , 2012 , 119 Suppl 2, S118-29	4	88
149	Prognostic factors in ovarian cancer. <i>Seminars in Oncology</i> , 1998 , 25, 305-14	5.5	87
148	Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy. <i>British Journal of Cancer</i> , 2018 , 119, 1075-1085	8.7	86
147	Gynecologic Cancer InterGroup (GCIIG) consensus review for ovarian germ cell tumors. <i>International Journal of Gynecological Cancer</i> , 2014 , 24, S48-54	3.5	81
146	Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology, The</i> , 2020 , 21, 1269-1282	21.7	80
145	The safety and efficacy of controlled ovarian hyperstimulation for fertility preservation in women with early breast cancer: a systematic review. <i>Human Reproduction</i> , 2017 , 32, 1033-1045	5.7	79
144	Caring for women with ovarian cancer in the last year of life: a longitudinal study of caregiver quality of life, distress and unmet needs. <i>Gynecologic Oncology</i> , 2014 , 132, 690-7	4.9	78
143	If I am in the mood, I enjoy it: an exploration of cancer-related fatigue and sexual functioning in women with breast cancer. <i>Oncologist</i> , 2011 , 16, 1333-44	5.7	75
142	LRP1B deletion in high-grade serous ovarian cancers is associated with acquired chemotherapy resistance to liposomal doxorubicin. <i>Cancer Research</i> , 2012 , 72, 4060-73	10.1	73
141	Anti-Müllerian hormone serum concentrations of women with germline BRCA1 or BRCA2 mutations. <i>Human Reproduction</i> , 2016 , 31, 1126-32	5.7	72
140	Fatigue states after cancer treatment occur both in association with, and independent of, mood disorder: a longitudinal study. <i>BMC Cancer</i> , 2006 , 6, 240	4.8	69
139	Gynecologic Cancer InterGroup (GCIIG) consensus review for mucinous ovarian carcinoma. <i>International Journal of Gynecological Cancer</i> , 2014 , 24, S14-9	3.5	64
138	Guidelines for the treatment of recurrent and metastatic cervical cancer. <i>Oncologist</i> , 2002 , 7, 342-7	5.7	64
137	Olaparib maintenance therapy in patients with platinum-sensitive, relapsed serous ovarian cancer and a BRCA mutation: Overall survival adjusted for postprogression poly(adenosine diphosphate ribose) polymerase inhibitor therapy. <i>Cancer</i> , 2016 , 122, 1844-52	6.4	62
136	Cancer of the ovary, fallopian tube, and peritoneum. <i>International Journal of Gynecology and Obstetrics</i> , 2015 , 131 Suppl 2, S111-22	4	61

135	Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial. <i>Lancet Oncology, The</i> , 2021 , 22, 620-631	21.7	58
134	Defining the Most Appropriate Primary End Point in Phase 2 Trials of Immune Checkpoint Inhibitors for Advanced Solid Cancers: A Systematic Review and Meta-analysis. <i>JAMA Oncology</i> , 2018 , 4, 522-528	13.4	56
133	Outcomes and endpoints in cancer trials: bridging the divide. <i>Lancet Oncology, The</i> , 2015 , 16, e43-52	21.7	56
132	Gynecologic Cancer InterGroup (GCIg) consensus review for endometrial stromal sarcoma. <i>International Journal of Gynecological Cancer</i> , 2014 , 24, S67-72	3.5	56
131	Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-escalation stage of a multicentre, open-label, phase 1a/b trial. <i>Lancet Oncology, The</i> , 2019 , 20, 1306-1315	21.7	52
130	The experience of cancer-related fatigue and chronic fatigue syndrome: a qualitative and comparative study. <i>Journal of Pain and Symptom Management</i> , 2007 , 34, 126-35	4.8	50
129	Quality of life during olaparib maintenance therapy in platinum-sensitive relapsed serous ovarian cancer. <i>British Journal of Cancer</i> , 2016 , 115, 1313-1320	8.7	47
128	Homologous Recombination DNA Repair Pathway Disruption and Retinoblastoma Protein Loss Are Associated with Exceptional Survival in High-Grade Serous Ovarian Cancer. <i>Clinical Cancer Research</i> , 2018 , 24, 569-580	12.9	46
127	Assessing health-related quality of life in gynecologic oncology: a systematic review of questionnaires and their ability to detect clinically important differences and change. <i>International Journal of Gynecological Cancer</i> , 2010 , 20, 664-84	3.5	46
126	Survival of Australian women with invasive epithelial ovarian cancer: a population-based study. <i>Medical Journal of Australia</i> , 2014 , 201, 283-8	4	44
125	Gynecologic Cancer InterGroup (GCIg) consensus review for clear cell carcinoma of the uterine corpus and cervix. <i>International Journal of Gynecological Cancer</i> , 2014 , 24, S90-5	3.5	43
124	BRCA1/2 mutations associated with progression-free survival in ovarian cancer patients in the AGO-OVAR 16 study. <i>Gynecologic Oncology</i> , 2016 , 140, 443-9	4.9	41
123	The acceptability, feasibility, and efficacy (phase I/II study) of the OVERcome (Olive Oil, Vaginal Exercise, and Moisturizer) intervention to improve dyspareunia and alleviate sexual problems in women with breast cancer. <i>Journal of Sexual Medicine</i> , 2013 , 10, 2549-58	1.1	40
122	Prevalence and predictors of insomnia in women with invasive ovarian cancer: anxiety a major factor. <i>European Journal of Cancer</i> , 2009 , 45, 3262-70	7.5	39
121	The impact of aromatase inhibitors on sexual functioning: current knowledge and future research directions. <i>Breast</i> , 2008 , 17, 436-40	3.6	38
120	Clinical and genetic predictors of paclitaxel neurotoxicity based on patient- versus clinician-reported incidence and severity of neurotoxicity in the ICON7 trial. <i>Annals of Oncology</i> , 2017 , 28, 2733-2740	10.3	37
119	Inflammatory Myofibroblastic Tumors of the Female Genital Tract Are Under-recognized: A Low Threshold for ALK Immunohistochemistry Is Required. <i>American Journal of Surgical Pathology</i> , 2017 , 41, 1433-1442	6.7	36
118	Prognostic factors in ovarian cancer. <i>Seminars in Oncology</i> , 1991 , 18, 205-12	5.5	36

117	Do BRCA1 and BRCA2 mutation carriers have earlier natural menopause than their noncarrier relatives? Results from the Kathleen Cunningham Foundation Consortium for Research into Familial Breast Cancer. <i>Journal of Clinical Oncology</i> , 2013 , 31, 3920-5	2.2	35
116	Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants. <i>Genetics in Medicine</i> , 2020 , 22, 1653-1666	8.1	34
115	Carboplatin hypersensitivity reactions: re-treatment with cisplatin desensitisation. <i>Gynecologic Oncology</i> , 2003 , 89, 112-5	4.9	33
114	Communication and information needs of women diagnosed with ovarian cancer regarding treatment-focused genetic testing. <i>Oncology Nursing Forum</i> , 2013 , 40, 275-83	1.7	32
113	A clinical guide to the management of genitourinary symptoms in breast cancer survivors on endocrine therapy. <i>Therapeutic Advances in Medical Oncology</i> , 2017 , 9, 269-285	5.4	30
112	Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients. <i>European Journal of Cancer</i> , 2017 , 82, 237-246	7.5	30
111	The patient-reported outcome content of international ovarian cancer randomised controlled trial protocols. <i>Quality of Life Research</i> , 2016 , 25, 2457-2465	3.7	30
110	A randomized Phase II study of veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in BRCA1/2 metastatic breast cancer: design and rationale. <i>Future Oncology</i> , 2017 , 13, 307-320	3.6	30
109	Gynecologic Cancer InterGroup (GCIg) consensus review for carcinoid tumors of the ovary. <i>International Journal of Gynecological Cancer</i> , 2014 , 24, S35-41	3.5	30
108	Randomized Evaluation of Cognitive-Behavioral Therapy and Graded Exercise Therapy for Post-Cancer Fatigue. <i>Journal of Pain and Symptom Management</i> , 2017 , 54, 74-84	4.8	29
107	Chemotherapy for epithelial ovarian, fallopian tube and primary peritoneal cancer. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , 2017 , 41, 126-138	4.6	29
106	Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , 2021 , 22, 1721-1731	21.7	29
105	Efficacy of Maintenance Olaparib for Patients With Newly Diagnosed Advanced Ovarian Cancer With a BRCA Mutation: Subgroup Analysis Findings From the SOLO1 Trial. <i>Journal of Clinical Oncology</i> , 2020 , 38, 3528-3537	2.2	29
104	An Exercise Intervention During Chemotherapy for Women With Recurrent Ovarian Cancer: A Feasibility Study. <i>International Journal of Gynecological Cancer</i> , 2015 , 25, 985-92	3.5	28
103	Impact of secondary cytoreductive surgery on survival in patients with platinum sensitive recurrent ovarian cancer: analysis of the CALYPSO trial. <i>Gynecologic Oncology</i> , 2015 , 136, 18-24	4.9	28
102	Gynecologic Cancer InterGroup (GCIg) consensus review for ovarian small cell cancers. <i>International Journal of Gynecological Cancer</i> , 2014 , 24, S30-4	3.5	28
101	Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus. <i>Breast Cancer Research</i> , 2016 , 18, 64	8.3	25
100	Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: Recommendations on incorporating patient-reported outcomes in clinical trials in epithelial ovarian cancer. <i>European Journal of Cancer</i> , 2017 , 78, 133-138	7.5	24

99	Quantifying physical activity and the associated barriers for women with ovarian cancer. <i>International Journal of Gynecological Cancer</i> , 2015 , 25, 577-83	3.5	24
98	Progression-free survival by local investigator versus independent central review: comparative analysis of the AGO-OVAR16 Trial. <i>Gynecologic Oncology</i> , 2015 , 136, 37-42	4.9	24
97	PARAGON: A Phase II study of anastrozole in patients with estrogen receptor-positive recurrent/metastatic low-grade ovarian cancers and serous borderline ovarian tumors. <i>Gynecologic Oncology</i> , 2019 , 154, 531-538	4.9	23
96	Early decline in cancer antigen 125 as a surrogate for progression-free survival in recurrent ovarian cancer. <i>Journal of the National Cancer Institute</i> , 2011 , 103, 1338-42	9.7	23
95	Symptom control in patients with recurrent ovarian cancer: measuring the benefit of palliative chemotherapy in women with platinum refractory/resistant ovarian cancer. <i>International Journal of Gynecological Cancer</i> , 2009 , 19 Suppl 2, S44-8	3.5	23
94	Moving toward personalized medicine: treatment-focused genetic testing of women newly diagnosed with ovarian cancer. <i>International Journal of Gynecological Cancer</i> , 2010 , 20, 704-16	3.5	22
93	Challenges to the development of new agents for molecularly defined patient subsets: lessons from BRCA1/2-associated breast cancer. <i>Journal of Clinical Oncology</i> , 2011 , 29, 4224-6	2.2	21
92	The impact of ethnicity on efficacy and toxicity of cyclin D kinase 4/6 inhibitors in advanced breast cancer: a meta-analysis. <i>Breast Cancer Research and Treatment</i> , 2019 , 174, 271-278	4.4	21
91	How should we discuss genetic testing with women newly diagnosed with breast cancer? Design and implementation of a randomized controlled trial of two models of delivering education about treatment-focused genetic testing to younger women newly diagnosed with breast cancer. <i>BMC Cancer</i> , 2012 , 12, 320	4.8	20
90	Hormonal treatment in recurrent and metastatic gynaecological cancers: a review of the current literature. <i>Current Oncology Reports</i> , 2013 , 15, 541-8	6.3	20
89	Commentary on the clinical trial reported by: Tewari KS, Sill M, Long III HJ, et al. Incorporation of bevacizumab in the treatment of recurrent and metastatic cervical cancer: a phase III randomized trial of the Gynecologic Oncology Group. <i>J Clin Oncol</i> 2013;(suppl; abstr 3). <i>Chinese Clinical Oncology</i> , 2014 , 3, 6	2.3	20
88	Clinically significant long-term maintenance treatment with olaparib in patients (pts) with platinum-sensitive relapsed serous ovarian cancer (PSR SOC).. <i>Journal of Clinical Oncology</i> , 2017 , 35, 5533-5533 ¹⁹		
87	Practical guidance on the use of olaparib capsules as maintenance therapy for women with BRCA mutations and platinum-sensitive recurrent ovarian cancer. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2016 , 12, 323-331	1.9	19
86	Phase 2 study of anastrozole in recurrent estrogen (ER)/progesterone (PR) positive endometrial cancer: The PARAGON trial - ANZGOG 0903. <i>Gynecologic Oncology</i> , 2019 , 154, 29-37	4.9	18
85	Quality of life and patient-reported outcomes in endometrial cancer clinical trials: a call for action!. <i>International Journal of Gynecological Cancer</i> , 2014 , 24, 1693-9	3.5	18
84	Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancer. <i>Oncotarget</i> , 2017 , 8, 47154-47160	3.3	18
83	Impact of molecular profiling on overall survival of patients with advanced ovarian cancer. <i>Oncotarget</i> , 2016 , 7, 19840-9	3.3	18
82	Quality of life in patients with advanced epithelial ovarian cancer (EOC) randomized to maintenance pazopanib or placebo after first-line chemotherapy in the AGO-OVAR 16 trial. Measuring what matters-patient-centered end points in trials of maintenance therapy. <i>Annals of Oncology</i> , 2018 , 29, 737-743	10.3	17

81	Coping strategies, trajectories, and their associations with patient-reported outcomes among women with ovarian cancer. <i>Supportive Care in Cancer</i> , 2018 , 26, 4133-4142	3.9	17
80	Patient-reported outcomes in ovarian cancer clinical trials. <i>Annals of Oncology</i> , 2013 , 24 Suppl 10, x64-x68.	3	17
79	Survival Following Chemotherapy in Ovarian Clear Cell Carcinoma Is Not Associated with Pathological Misclassification of Tumor Histotype. <i>Clinical Cancer Research</i> , 2019 , 25, 3962-3973	12.9	16
78	Prospective study of breast cancer risk for mutation negative women from BRCA1 or BRCA2 mutation positive families. <i>Breast Cancer Research and Treatment</i> , 2011 , 130, 1057-61	4.4	16
77	Optimizing Clinical Screening for Chemotherapy-Induced Peripheral Neuropathy. <i>Journal of Pain and Symptom Management</i> , 2019 , 58, 1023-1032	4.8	15
76	Recreational Physical Activity Is Associated with Reduced Breast Cancer Risk in Adult Women at High Risk for Breast Cancer: A Cohort Study of Women Selected for Familial and Genetic Risk. <i>Cancer Research</i> , 2020 , 80, 116-125	10.1	15
75	Validation of the modified Glasgow Prognostic Score (mGPS) in recurrent ovarian cancer (ROC) - Analysis of patients enrolled in the GCIIG Symptom Benefit Study (SBS). <i>Gynecologic Oncology</i> , 2018 , 148, 36-41	4.9	15
74	Reducing Uncertainty: Predictors of Stopping Chemotherapy Early and Shortened Survival Time in Platinum Resistant/Refractory Ovarian Cancer-The GCIIG Symptom Benefit Study. <i>Oncologist</i> , 2017 , 22, 1117-1124	5.7	14
73	A systematic evaluation of compliance and reporting of patient-reported outcome endpoints in ovarian cancer randomised controlled trials: implications for generalisability and clinical practice. <i>Journal of Patient-Reported Outcomes</i> , 2017 , 1, 5	2.6	14
72	Cancer of the ovary, fallopian tube, and peritoneum: 2021 update. <i>International Journal of Gynecology and Obstetrics</i> , 2021 , 155 Suppl 1, 61-85	4	14
71	Patient-centred outcomes and effect of disease progression on health status in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation receiving maintenance olaparib or placebo (SOLO1): a randomised, phase 3 trial. <i>Lancet Oncology</i> , 2021 , 22, 632-642	21.7	14
70	Does adjuvant chemotherapy dose modification have an impact on the outcome of patients diagnosed with advanced stage ovarian cancer? An NRG Oncology/Gynecologic Oncology Group study. <i>Gynecologic Oncology</i> , 2018 , 151, 18-23	4.9	13
69	Feasibility, acceptability and preferences for intraperitoneal chemotherapy with paclitaxel and cisplatin after optimal debulking surgery for ovarian and related cancers: an ANZGOG study. <i>Journal of Gynecologic Oncology</i> , 2013 , 24, 359-66	4	13
68	Health-related quality of life (HRQOL) and patient-centered outcomes with maintenance olaparib compared with placebo following chemotherapy in patients with germline (g) BRCA-mutated (m) platinum-sensitive relapsed serous ovarian cancer (PSR SOC): SOLO2 phase III trial.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 5587-5597	2.2	13
67	Variations in adjuvant chemotherapy and survival in women with epithelial ovarian cancer - a population-based study. <i>Acta Oncologica</i> , 2016 , 55, 226-33	3.2	12
66	Balance Deficits and Functional Disability in Cancer Survivors Exposed to Neurotoxic Cancer Treatments. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019 , 17, 949-955	7.3	12
65	Development and validation of a prognostic nomogram for overall survival in patients with platinum-resistant ovarian cancer treated with chemotherapy. <i>European Journal of Cancer</i> , 2019 , 117, 99-106	7.5	11
64	Carboplatin dosing in ovarian cancer: problems and pitfalls. <i>International Journal of Gynecological Cancer</i> , 2011 , 21, 1213-8	3.5	11

63	The role of poly adenosine diphosphate ribose polymerase inhibitors in breast and ovarian cancer: current status and future directions. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2011 , 7, 197-211	1.9	11
62	Helplessness/hopelessness, minimization and optimism predict survival in women with invasive ovarian cancer: a role for targeted support during initial treatment decision-making?. <i>Supportive Care in Cancer</i> , 2016 , 24, 2627-34	3.9	11
61	OVQUEST - Life after the diagnosis and treatment of ovarian cancer - An international survey of symptoms and concerns in ovarian cancer survivors. <i>Gynecologic Oncology</i> , 2019 , 155, 126-134	4.9	10
60	What is the role of retroperitoneal exploration in optimally debulked stage IIIC epithelial ovarian cancer? An NRG Oncology/Gynecologic Oncology Group ancillary data study. <i>Cancer</i> , 2017 , 123, 985-993	6.4	10
59	Cutaneous adverse effects of hormonal adjuvant therapy for breast cancer: a case of localised urticarial vasculitis following anastrozole therapy and a review of the literature. <i>Australasian Journal of Dermatology</i> , 2014 , 55, 282-5	1.3	10
58	A specialist breast care nurse role for women with metastatic breast cancer: enhancing supportive care. <i>Oncology Nursing Forum</i> , 2011 , 38, 627-31	1.7	10
57	PARAGON (ANZGOG-0903): a phase 2 study of anastrozole in asymptomatic patients with estrogen and progesterone receptor-positive recurrent ovarian cancer and CA125 progression. <i>Journal of Gynecologic Oncology</i> , 2019 , 30, e86	4	10
56	The Influence of Number and Timing of Pregnancies on Breast Cancer Risk for Women With or Mutations. <i>JNCI Cancer Spectrum</i> , 2018 , 2, pky078	4.6	10
55	Stage IB2 adenosquamous cervical cancer diagnosed at 19-weeks gestation. <i>Australian and New Zealand Journal of Obstetrics and Gynaecology</i> , 2015 , 55, 94-7	1.7	9
54	Alcohol Consumption, Cigarette Smoking, and Risk of Breast Cancer for and Mutation Carriers: Results from The BRCA1 and BRCA2 Cohort Consortium. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020 , 29, 368-378	4	9
53	Phase 1 trial of olaparib and oral cyclophosphamide in BRCA breast cancer, recurrent BRCA ovarian cancer, non-BRCA triple-negative breast cancer, and non-BRCA ovarian cancer. <i>British Journal of Cancer</i> , 2019 , 120, 279-285	8.7	9
52	Efficacy of immune checkpoint inhibitors in older adults with advanced stage cancers: A meta-analysis. <i>Journal of Geriatric Oncology</i> , 2020 , 11, 508-514	3.6	9
51	Validation of Progression-Free Survival Rate at 6 Months and Objective Response for Estimating Overall Survival in Immune Checkpoint Inhibitor Trials: A Systematic Review and Meta-analysis. <i>JAMA Network Open</i> , 2020 , 3, e2011809	10.4	8
50	Frequency, severity and timing of common adverse events (AEs) with maintenance olaparib in patients (pts) with platinum-sensitive relapsed serous ovarian cancer (PSR SOC).. <i>Journal of Clinical Oncology</i> , 2015 , 33, 5550-5550	2.2	7
49	When will I feel normal again? Trajectories and predictors of persistent symptoms and poor wellbeing after primary chemotherapy for ovarian cancer. <i>Gynecologic Oncology</i> , 2020 , 159, 179-186	4.9	6
48	A practical guide to understanding, using and including patient reported outcomes in clinical trials in ovarian cancer. <i>Journal of Gynecologic Oncology</i> , 2018 , 29, e81	4	6
47	Neoadjuvant chemoradiation (modified Eilber protocol) versus adjuvant radiotherapy in the treatment of extremity soft tissue sarcoma. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2016 , 60, 539-44	1.7	6
46	The impact of obesity on neuropathy outcomes for paclitaxel- and oxaliplatin-treated cancer survivors. <i>Journal of Cancer Survivorship</i> , 2021 , 1	5.1	6

45	Medicare-funded cancer genetic tests: a note of caution. <i>Medical Journal of Australia</i> , 2018 , 209, 193-196		6
44	Adequacy of risk-reducing gynaecologic surgery in BRCA1 or BRCA2 mutation carriers and other women at high risk of pelvic serous cancer. <i>Familial Cancer</i> , 2011 , 10, 505-14	3	5
43	Role of systemic chemotherapy in metastatic cervical cancer. <i>Expert Review of Anticancer Therapy</i> , 2003 , 3, 234-40	3.5	4
42	Where have we gone wrong? Phase II trials (Ph2t) do not inform the results of phase III trials (Ph3t) in platinum resistant ovarian cancer (PROC).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 5559-5559	2.2	4
41	The hidden burden of anxiety and depression in ovarian cancer: A prospective longitudinal study from diagnosis.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 10081-10081	2.2	4
40	Practical considerations for clinicians for transitioning patients on maintenance therapy with olaparib capsules to the tablet formulation of olaparib. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2018 , 14, 459-464	1.9	4
39	A phase 2 study of anastrozole in patients with oestrogen receptor and/progesterone receptor positive recurrent/metastatic granulosa cell tumours/sex-cord stromal tumours of the ovary: The PARAGON/ANZGOG 0903 trial. <i>Gynecologic Oncology</i> , 2021 , 163, 72-78	4.9	4
38	Breast Cancer Chemoprevention: Use and Views of Australian Women and Their Clinicians. <i>Cancer Prevention Research</i> , 2021 , 14, 131-144	3.2	3
37	Predictors of progression free survival, overall survival and early cessation of chemotherapy in women with potentially platinum sensitive (PPS) recurrent ovarian cancer (ROC) starting third or subsequent line(B) chemotherapy - The GCIG symptom benefit study (SBS). <i>Gynecologic Oncology</i> , 2020 , 156, 45-53	4.9	3
36	Concordance between CA-125 and RECIST progression in patients with germline BRCA-mutated platinum-sensitive relapsed ovarian cancer treated in the SOLO2 trial with olaparib as maintenance therapy after response to chemotherapy. <i>European Journal of Cancer</i> , 2020 , 139, 59-67	7.5	3
35	Relevance of Platinum-free Interval and Reversion Mutations for Veliparib Monotherapy after Progression on Carboplatin/Paclitaxel for g Advanced Breast Cancer (BROCADE3 Crossover). <i>Clinical Cancer Research</i> , 2021 , 27, 4983-4993	12.9	3
34	Do all patients with recurrent ovarian cancer need systemic therapy?. <i>Cancer</i> , 2019 , 125 Suppl 24, 4602-4608	4.9	3
33	Pre- and Post-Diagnosis Diet Quality and Ovarian Cancer Survival. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021 , 30, 229-232	4	3
32	Tumor Response End Points as Surrogates for Overall Survival in Immune Checkpoint Inhibitor Trials: A Systematic Review and Meta-Analysis. <i>JCO Precision Oncology</i> , 2021 , 5,	3.6	3
31	Improved quality of risk-reducing salpingo-oophorectomy in Australasian women at high risk of pelvic serous cancer. <i>Familial Cancer</i> , 2017 , 16, 461-469	3	2
30	Anti-Müllerian Hormone Serum Concentrations of Women With Germline BRCA1 or BRCA2 Mutations. <i>Obstetrical and Gynecological Survey</i> , 2016 , 71, 474-475	2.4	2
29	Getting the most out of follow-up: A prospective study using the Measure of Ovarian Symptoms and Treatment concerns (MOST) symptom index to evaluate and track adverse effects (AEs) and detect symptoms of recurrence in patients with ovarian cancer (OC) following first line chemotherapy (1LT).. <i>Journal of Clinical Oncology</i> , 2018 , 36, 10062-10062	2.2	2
28	Efficacy of maintenance olaparib for newly diagnosed, advanced ovarian cancer patients (pts) by BRCA1 or BRCA2 mutation in the phase III SOLO1 trial.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 5551-5551	2.2	2

27	The validity of progression-free survival 2 as a surrogate trial end point for overall survival.. <i>Cancer</i> , 2022 ,	6.4	2
26	Identification of a Locus Near Associated With Progression-Free Survival in Ovarian Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021 , 30, 1669-1680	4	2
25	Bilateral Salpingo-oophorectomy and Breast Cancer Risk for and Mutation Carriers: Assessing the Evidence. <i>Cancer Prevention Research</i> , 2021 , 14, 983-994	3.2	2
24	Getting the MOST out of follow-up: a randomized controlled trial comparing 3 monthly nurse led follow-up via telehealth, including monitoring CA125 and patient reported outcomes using the MOST (Measure of Ovarian Symptoms and Treatment concerns) with routine clinic based or	3.5	2
23	Efficacy and safety of first-line veliparib and carboplatin-paclitaxel in patients with HER2- advanced germline BRCA+ breast cancer: Subgroup analysis of a randomised clinical trial. <i>European Journal of Cancer</i> , 2021 , 154, 35-45	7.5	2
22	Risk of uterine cancer in BRCA1 and BRCA2 mutation carriers.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 1529-1529	2.2	1
21	Quality of life (QOL) to predict overall survival (OS) in women with platinum-resistant ovarian cancer (PROC).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 5575-5575	2.2	1
20	Targeting the actin/tropomyosin cytoskeleton in epithelial ovarian cancer reveals multiple mechanisms of synergy with anti-microtubule agents. <i>British Journal of Cancer</i> , 2021 , 125, 265-276	8.7	1
19	Incorporating patient centered benefits as endpoints in randomized trials of maintenance therapies in advanced ovarian cancer: A position paper from the GCIIG symptom benefit committee. <i>Gynecologic Oncology</i> , 2021 , 161, 502-507	4.9	1
18	Communicating BRCA research results to patients enrolled in international clinical trials: lessons learnt from the AGO-OVAR 16 study. <i>BMC Medical Ethics</i> , 2016 , 17, 63	2.9	1
17	The value of participating in clinical trials: the whole is greater than the sum of its parts. <i>Medical Journal of Australia</i> , 2018 , 209, 424-425	4	1
16	Tolerability of maintenance olaparib in newly diagnosed patients with advanced ovarian cancer and a BRCA mutation in the randomized phase III SOLO1 trial. <i>Gynecologic Oncology</i> , 2021 , 163, 41-49	4.9	1
15	Progression-free survival by investigator versus blinded independent central review in newly diagnosed patients with high-grade serous ovarian cancer: Analysis of the VELIA/GOG-3005 trial. <i>Gynecologic Oncology</i> , 2021 , 162, 375-381	4.9	1
14	Prognostic nomogram for progression-free survival in patients with BRCA mutations and platinum-sensitive recurrent ovarian cancer on maintenance olaparib therapy following response to chemotherapy. <i>European Journal of Cancer</i> , 2021 , 154, 190-200	7.5	1
13	The Impasse on Overall Survival in Oncology Reimbursement Decision-Making: How Can We Resolve This?. <i>Cancer Management and Research</i> , 2021 , 13, 8457-8471	3.6	0
12	Recreational Physical Activity and Outcomes After Breast Cancer in Women at High Familial Risk.. <i>JNCI Cancer Spectrum</i> , 2021 , 5, pkab090	4.6	0
11	Adverse events in the placebo arm of maintenance therapy trials in advanced ovarian cancer: A systematic review and meta-analysis. <i>European Journal of Cancer</i> , 2022 , 170, 169-178	7.5	0
10	Peritoneal hepatoid carcinoma with chemotherapy response and possible stem cell involvement. <i>Human Pathology: Case Reports</i> , 2018 , 12, 71-76	0.2	

- 9 Tumour profiling for treatment of patients with ovarian cancers. *Pathology*, **2018**, 50, S77 1.6
- 8 Reply to M.G. McNamara et al and M.S. Copur et al. *Journal of Clinical Oncology*, **2015**, 33, 2583-4 2.2
- 7 A response to the forgotten fallopian tube. *Nature Reviews Cancer*, **2011**, 11, 227-227 31.3
- 6 Pregnancy induced hyperplasia of residual breast tissue following risk reducing contralateral mastectomy - simply interesting or a clinically important observation.. *Cancer Treatment and Research Communications*, **2022**, 30, 100504 2
- 5 Management of Rare Uterine Malignant Tumors **2020**, 277-312
- 4 Squamous Cell Carcinomas Arising From Dermoids **2011**, 131-133
- 3 Response as a Measure of Treatment Efficacy in Clinical Trials: Should RECIST Be Abandoned? **2014**, 91-100
- 2 The development of drug resistance through reversion mutation in BRCA genes in ovarian cancer **2021**, 43-53
- 1 TRACEBACK: Testing of Historical Tubo-Ovarian Cancer Patients for Hereditary Risk Genes as a Cancer Prevention Strategy in Family Members.. *Journal of Clinical Oncology*, **2022**, JCO2102108 2.2